Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

18 November 2005

journal article
research article
Published by Wolters Kluwer Health in AIDS

Vol. 19 (17) , 2036-2038
https://doi.org/10.1097/01.aids.0000189563.79976.05

Abstract

Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not require antiretroviral therapy.

Keywords

This publication has 12 references indexed in Scilit:

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
AIDS, 2005
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel
AIDS, 2005
Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis B
Hepatology, 2003
Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine
Antimicrobial Agents and Chemotherapy, 2002
Adefovir and Tenofovir Susceptibilities of HIV-1 After 24 to 48 Weeks of Adefovir Dipivoxil Therapy: Genotypic and Phenotypic Analyses of Study GS-96-408
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
Hepatology, 2000
Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral TherapyA Randomized Controlled Trial
JAMA, 1999
Human Immunodeficiency Virus Type 1 Expressing the Lamivudine‐Associated M184V Mutation in Reverse Transcriptase Shows Increased Susceptibility to Adefovir and Decreased Replication Capability In Vitro
The Journal of Infectious Diseases, 1999
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
Antiviral Research, 1996
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine
Antimicrobial Agents and Chemotherapy, 1995